EPS for Agios Pharmaceuticals Inc (AGIO) Expected At $-1.74

October 14, 2017 - By Max Morgan

 EPS for Agios Pharmaceuticals Inc (AGIO) Expected At $ 1.74
Investors sentiment increased to 2.04 in 2017 Q2. Its up 0.71, from 1.33 in 2017Q1. It improved, as 14 investors sold Agios Pharmaceuticals Inc shares while 32 reduced holdings. 22 funds opened positions while 72 raised stakes. 44.72 million shares or 14.71% more from 38.98 million shares in 2017Q1 were reported.
Fiera Cap Corp invested in 48,697 shares. Meeder Asset Incorporated holds 63 shares. Whittier Of Nevada holds 140 shares. Ecor1 Cap Ltd Co accumulated 23,300 shares. Clearbridge Invs Lc has invested 0.08% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Eaton Vance Mgmt stated it has 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Point72 Asset Mgmt Limited Partnership reported 0.06% stake. Moreover, Spark Investment Management Ltd Liability Corporation has 0.27% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Royal Bancorporation Of Canada accumulated 0% or 9,131 shares. Guggenheim Limited Liability Com has 62,462 shares. C Worldwide Gru Holdings A S reported 1,600 shares. Sei Invs Co accumulated 0% or 23 shares. Hood River Capital Ltd Llc has 0.42% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Cap Invsts has invested 0.22% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Moreover, Teachers Retirement Sys Of The State Of Kentucky has 0.03% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Since May 1, 2017, it had 0 buys, and 4 insider sales for $497,855 activity. $150,180 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Schenkein David P. Shares for $101,730 were sold by Cantley Lewis Clayton Jr..

Wall Street await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to release earnings on November, 2. Analysts forecast earnings per share of $-1.74, down exactly $0.11 or 6.75 % from 2014’s $-1.63 EPS. After posting $-1.78 EPS for the previous quarter, Agios Pharmaceuticals Inc’s analysts now forecast -2.25 % EPS growth. The stock decreased 1.35% or $0.98 during the last trading session, reaching $71.35. About 245,472 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since October 14, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 38 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was upgraded by Canaccord Genuity to “Buy” on Monday, June 13. Oppenheimer maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Tuesday, August 1. Oppenheimer has “Buy” rating and $7500 target. The firm earned “Neutral” rating on Friday, August 19 by BTIG Research. Oppenheimer maintained the shares of AGIO in report on Monday, June 26 with “Buy” rating. The firm has “Buy” rating given on Tuesday, August 1 by Cowen & Co. The company was maintained on Tuesday, August 8 by Cowen & Co. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Hold” rating by Roth Capital on Wednesday, August 5. As per Monday, September 18, the company rating was maintained by J.P. Morgan. The firm earned “Buy” rating on Thursday, June 1 by Oppenheimer. The rating was initiated by SunTrust with “Buy” on Wednesday, March 30.

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $3.45 billion. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. It currently has negative earnings. The Company’s cancer product candidates are enasidenib and ivosidenib , which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

More important recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Agios: Smooth First Mover In Cancer Metabolism” on August 08, 2017, also Seekingalpha.com published article titled: “Agios, Amigos!”, Bostonglobe.com published: “Cambridge biotech Agios wins OK for its leukemia drug” on August 01, 2017. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) was released by: Nasdaq.com and their article: “Agios Pharmaceuticals Inc (AGIO) CEO David P Schenkein Sold $5.6 million of Shares” with publication date: October 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com